BiotechTube
Milagen

Milagen

San Francisco, United States· Est.
milagen.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $4.2M

Overview

Milagen, founded in 2015 and based in San Francisco, is a diagnostics company developing blood-based tests for the early detection of cancer recurrence and therapy monitoring. Its core technology is a proprietary proteomics platform used to discover and validate protein biomarkers found in blood serum. The company currently offers two CLIA lab tests, MammoCheck for breast cancer and IgoCheck for colorectal cancer, with a pipeline targeting lung, ovarian, and prostate cancers. Led by a scientifically experienced team, Milagen operates as a private, likely pre-revenue entity seeking partnerships and investment to advance its product portfolio.

Oncology

Technology Platform

Proprietary proteomics platform for discovering and validating protein biomarkers secreted into blood serum, used to develop immunoassays for early cancer detection and recurrence monitoring.

Funding History

1
Total raised:$4.2M
Seed$4.2M

Opportunities

The large and growing market for cancer monitoring and early detection, driven by an aging population and emphasis on personalized medicine, presents a major opportunity.
Successfully expanding from recurrence monitoring into the multi-billion dollar multi-cancer early detection (MCED) screening market could be transformative.
Forming partnerships with pharmaceutical companies for therapy response monitoring or with larger diagnostic firms for commercialization could provide critical resources and market access.

Risk Factors

Intense competition from established diagnostic companies and newer liquid biopsy firms using ctDNA technology poses a significant market risk.
Achieving widespread clinical adoption and insurance reimbursement for its CLIA lab tests without FDA approval is a major commercial hurdle.
The company's ability to secure sufficient funding to validate its pipeline and execute its commercial strategy is a critical financial risk.

Competitive Landscape

Milagen competes in the crowded liquid biopsy and cancer diagnostics space. Key competitors include large, diversified diagnostics companies like Roche, Abbott, and Thermo Fisher, as well as focused players like Exact Sciences (Cologuard, Oncotype DX) and Guardant Health (Guardant360, Shield). In multi-cancer early detection, GRAIL (now part of Illumina) is a dominant force. Milagen's differentiation lies in its protein-based biomarker approach, but it must prove superior or complementary clinical utility against entrenched ctDNA-based methods.

More companies in Diagnostics & Precision Medicine →More companies in United States →